Russo G E, Giusti S, Vitaliano E, Caramiello M S, Maurici M, De Marco C M, Pennacchia M, D'Auria F, Bonello M, Bruno C, Marigliano V
Istituto Clinica Medica I, Ambulatorio di Dialisi e Plasmaferesi, Università di Roma La Sapienza.
Clin Ter. 1997 Mar;148(3):89-93.
We followed for a period of six months, 54 patients of over 60 years old, submitted to hemodialitic treatment. We gave human recombinant erythropoietin, average dosage 50 UI/Kg subcutaneously on alternative days, folic acid and iron supplements together with a proteic supply of 1.2 g/Kg/die (35 Kcal/Kg). The medullary response has been monitored with hematochemical tests; blood pressure and nutritional conditions have been evaluated. Furthermore, the patients were given a questionnaire to evaluate their quality of life. At the end of the follow up, 50 patients responded positively to therapy. These patients showed an increase of RBC (from 2,789,780 +/- 259,310 to 3,313,110 +/- 472,780 p < 0.001) of HCT (from 21.86% +/- 2.16% to 27.18 +/- 2.74% p < 0.0001) and of Hb (from 7.72 +/- 1.12 g/dl to 9.28 +/- 0.98 g/dl p < 0.006). Total protein and albumin increased too. Furthermore they showed a progressive increase of "performance status". Our results confirm efficacy of erythropoietin in the treatment of anemia in elderly hemodialized patients.
我们对54名60岁以上接受血液透析治疗的患者进行了为期6个月的随访。我们给予人类重组促红细胞生成素，平均剂量为50 UI/Kg，隔日皮下注射，同时给予叶酸和铁补充剂，并提供1.2 g/Kg/天（35 Kcal/Kg）的蛋白质供应。通过血液化学检测监测骨髓反应；评估血压和营养状况。此外，还向患者发放了问卷以评估他们的生活质量。随访结束时，50名患者对治疗反应良好。这些患者的红细胞（从2,789,780 +/- 259,310增至3,313,110 +/- 472,780，p < 0.001）、血细胞比容（从21.86% +/- 2.16%增至27.18 +/- 2.74%，p < 0.0001）和血红蛋白（从7.72 +/- 1.12 g/dl增至9.28 +/- 0.98 g/dl，p < 0.006）均有所增加。总蛋白和白蛋白也有所增加。此外，他们的“体能状态”逐渐改善。我们的结果证实了促红细胞生成素在治疗老年血液透析患者贫血方面的疗效。
